Global Radioligand Therapy Market Size, Demand, Opportunities, Forecast by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Radioligand Therapy Market Size Analysis

Global Radioligand Therapy Market Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value
U.S.
1. By Isotope
  1. Introduction
    1. Isotope By Value
  2. Lutetium-177 (Lu-177)
    1. By Value
  3. Actinium-225 (Ac-225)
    1. By Value
  4. Iodine-131 (I-131)
    1. By Value
  5. Other Isotopes
    1. By Value
2. By Target
  1. Introduction
    1. Target By Value
  2. Prostate-Specific Membrane Antigen
    1. By Value
  3. Ki 67 Expression and Grading
    1. By Value
  4. Cytochrome P450 17A1 Inhibitor
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Prostate Cancer
    1. By Value
  3. Neuroendocrine Tumours (NETs)
    1. By Value
  4. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers
    1. By Value
  4. Cancer Treatment Centers
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value
U.K.
1. By Isotope
  1. Introduction
    1. Isotope By Value
  2. Lutetium-177 (Lu-177)
    1. By Value
  3. Actinium-225 (Ac-225)
    1. By Value
  4. Iodine-131 (I-131)
    1. By Value
  5. Other Isotopes
    1. By Value
2. By Target
  1. Introduction
    1. Target By Value
  2. Prostate-Specific Membrane Antigen
    1. By Value
  3. Ki 67 Expression and Grading
    1. By Value
  4. Cytochrome P450 17A1 Inhibitor
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Prostate Cancer
    1. By Value
  3. Neuroendocrine Tumours (NETs)
    1. By Value
  4. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers
    1. By Value
  4. Cancer Treatment Centers
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value
China
1. By Isotope
  1. Introduction
    1. Isotope By Value
  2. Lutetium-177 (Lu-177)
    1. By Value
  3. Actinium-225 (Ac-225)
    1. By Value
  4. Iodine-131 (I-131)
    1. By Value
  5. Other Isotopes
    1. By Value
2. By Target
  1. Introduction
    1. Target By Value
  2. Prostate-Specific Membrane Antigen
    1. By Value
  3. Ki 67 Expression and Grading
    1. By Value
  4. Cytochrome P450 17A1 Inhibitor
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Prostate Cancer
    1. By Value
  3. Neuroendocrine Tumours (NETs)
    1. By Value
  4. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers
    1. By Value
  4. Cancer Treatment Centers
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value
UAE
1. By Isotope
  1. Introduction
    1. Isotope By Value
  2. Lutetium-177 (Lu-177)
    1. By Value
  3. Actinium-225 (Ac-225)
    1. By Value
  4. Iodine-131 (I-131)
    1. By Value
  5. Other Isotopes
    1. By Value
2. By Target
  1. Introduction
    1. Target By Value
  2. Prostate-Specific Membrane Antigen
    1. By Value
  3. Ki 67 Expression and Grading
    1. By Value
  4. Cytochrome P450 17A1 Inhibitor
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Prostate Cancer
    1. By Value
  3. Neuroendocrine Tumours (NETs)
    1. By Value
  4. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers
    1. By Value
  4. Cancer Treatment Centers
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Isotope
1. Introduction
  1. Isotope By Value
2. Lutetium-177 (Lu-177)
  1. By Value
3. Actinium-225 (Ac-225)
  1. By Value
4. Iodine-131 (I-131)
  1. By Value
5. Other Isotopes
  1. By Value
By Target
1. Introduction
  1. Target By Value
2. Prostate-Specific Membrane Antigen
  1. By Value
3. Ki 67 Expression and Grading
  1. By Value
4. Cytochrome P450 17A1 Inhibitor
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Prostate Cancer
  1. By Value
3. Neuroendocrine Tumours (NETs)
  1. By Value
4. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Ambulatory Surgical Centers
  1. By Value
4. Cancer Treatment Centers
  1. By Value
5. Others
  1. By Value
Brazil
1. By Isotope
  1. Introduction
    1. Isotope By Value
  2. Lutetium-177 (Lu-177)
    1. By Value
  3. Actinium-225 (Ac-225)
    1. By Value
  4. Iodine-131 (I-131)
    1. By Value
  5. Other Isotopes
    1. By Value
2. By Target
  1. Introduction
    1. Target By Value
  2. Prostate-Specific Membrane Antigen
    1. By Value
  3. Ki 67 Expression and Grading
    1. By Value
  4. Cytochrome P450 17A1 Inhibitor
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Prostate Cancer
    1. By Value
  3. Neuroendocrine Tumours (NETs)
    1. By Value
  4. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Ambulatory Surgical Centers
    1. By Value
  4. Cancer Treatment Centers
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Radioligand Therapy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Clovis Oncology
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Curium Pharma
Amneal Pharmaceuticals LLC
Novartis AG
Molecular Partners
Pfizer Inc.
Eli Lilly and Company (POINT Biopharma Global Inc.)
Fusion Pharmaceuticals Inc.
Telix Pharmaceuticals
Lantheus Holdings Inc.
Bayer AG
ITM Isotope Technologies Munich SE
Precirix
Radio Medix
Johnson & Johnson Services Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment